Syngene International (SYNGENE) Fundamentals 2026 — P/E 51.6x, Revenue Analysis | SniperIQ
Syngene International (SYNGENE) is a India-listed Healthcare company in Biotechnology with a market capitalization of ₹16,318 Crore, trading at ₹406.40 on the BSE. This SniperIQ fundamentals page covers Syngene International's valuation (P/E 51.6x, P/B 3.4x), profitability (net margin 8.5%), revenue (₹3,739 Crore in FY2026), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Syngene International's market cap?
Syngene International (SYNGENE) has a market capitalization of approximately ₹16,318 Crore, trading at ₹406.40 on the BSE. Market cap moves with the live share price.
What is Syngene International's P/E ratio?
Syngene International's trailing twelve-month P/E ratio is 51.6x, with a price-to-book (P/B) of 3.4x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Syngene International?
Syngene International runs a net profit margin of 8.5%, a gross margin of 43.7%, and an operating margin of 22.0%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Syngene International generate?
Syngene International reported revenue of ₹3,739 Crore for fiscal year 2026, with net income of ₹317 Crore and earnings per share (EPS) of 7.87. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Syngene International pay a dividend?
Syngene International offers a trailing dividend yield of about 0.3%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Syngene International financially healthy?
Syngene International carries a debt-to-equity ratio of 0.09x and a current ratio of 1.38x, with a market beta of -0.00. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Syngene International a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Syngene International (SYNGENE) the key facts are: market cap ₹16,318 Crore, P/E 51.6x, revenue ₹3,739 Crore, 52-week range 380-728.4. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Syngene International's full fundamentals live
Get Syngene International's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.